{"id":"tas-102-regorafenib-fruquintinib","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Hypertension"},{"rate":"10-20%","effect":"Hand-foot syndrome"},{"rate":"5-15%","effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL4303214","moleculeType":"Small molecule","molecularWeight":"393.40"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"TAS-102 works by incorporating into DNA and causing DNA damage, which triggers cell death in cancer cells. Regorafenib targets multiple kinases involved in tumor growth and angiogenesis, leading to reduced tumor size and progression. Fruquintinib selectively inhibits VEGFR2, which is crucial for tumor angiogenesis and growth.","oneSentence":"TAS-102 is a nucleoside analog that inhibits thymidylate synthase, leading to DNA damage in cancer cells. Regorafenib is a multi-kinase inhibitor that targets angiogenic, stromal, and tumor cells. Fruquintinib is a potent and highly selective inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:29.386Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Gastrointestinal stromal tumor"},{"name":"Colorectal cancer"}]},"trialDetails":[{"nctId":"NCT07483684","phase":"PHASE3","title":"A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2026-03","conditions":"HER2 IHC3+ Advanced Colorectal Cancer","enrollment":142},{"nctId":"NCT07384377","phase":"PHASE3","title":"JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2026-02-06","conditions":"HER2-positive Colorectal Cancer","enrollment":123},{"nctId":"NCT07353268","phase":"PHASE2","title":"Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy.","status":"NOT_YET_RECRUITING","sponsor":"Tao Zhang","startDate":"2026-01-21","conditions":"Colorectal Cancer","enrollment":76},{"nctId":"NCT06199973","phase":"PHASE3","title":"Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2024-03-01","conditions":"Advanced Colorectal Cancer","enrollment":130},{"nctId":"NCT03251378","phase":"PHASE1","title":"A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers","status":"COMPLETED","sponsor":"Hutchison Medipharma Limited","startDate":"2017-12-11","conditions":"Advanced Solid Tumors, Metastatic Colon Cancer, Metastatic Breast Cancer","enrollment":129},{"nctId":"NCT05993702","phase":"","title":"TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2023-09-01","conditions":"TAS 102, Regorafenib, Fruquintinib","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TAS-102, Regorafenib , Fruquintinib","genericName":"TAS-102, Regorafenib , Fruquintinib","companyName":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","companyId":"suzhou-suncadia-biopharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TAS-102 is a nucleoside analog that inhibits thymidylate synthase, leading to DNA damage in cancer cells. Regorafenib is a multi-kinase inhibitor that targets angiogenic, stromal, and tumor cells. Fruquintinib is a potent and highly selective inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2). Used for Metastatic colorectal cancer, Gastrointestinal stromal tumor, Colorectal cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}